Spahn T W, Fontana A, Faria A M, Slavin A J, Eugster H P, Zhang X, Koni P A, Ruddle N H, Flavell R A, Rennert P D, Weiner H L
Center for Neurologic Diseases, Brigham and Women's Hospital and Harvard Medical School, Boston, USA.
Eur J Immunol. 2001 Apr;31(4):1278-87. doi: 10.1002/1521-4141(200104)31:4<1278::aid-immu1278>3.0.co;2-a.
Systemic hyporesponsiveness occurs following oral administration of antigen (oral tolerance) and involves the uptake and processing of antigen by the gut-associated lymphoid tissue (GALT), which includes Peyer's patches (PP) lamina propria lymphocytes and mesenteric lymph nodes (MLN). Animals with targeted mutations of genes in the tumor necrosis factor (TNF) family have differential defects in the development of peripheral lymphoid organs including PP and MLN, and provide a unique opportunity to investigate the role of GALT structures in the induction of oral tolerance. Oral tolerance could not be induced in TNF/lymphotoxin (LT) alpha-/- mice, which are devoid of both PP and MLN, although these animals could be tolerized by intraperitoneal administration of antigen, demonstrating the requirement for GALT for oral tolerance induction. LTbeta-/- mice and LTalpha/LTbeta+/- animals do not have PP but could be orally tolerized, as measured by IFN-gamma production and delayed-type hypersensitivity responses by administration of both low or high doses of ovalbumin. To further investigate the requirement for PP, we tested the progeny of LTbeta-receptor-IgG-fusion-protein (LTbetaRigG)-treated mice, which do not form PP but have an otherwise intact immune system. Although these animals had decreased fecal IgA production, they could be orally tolerized. Our results demonstrate that PP are not an absolute requirement for the induction of either high- or low-dose oral tolerance, although oral tolerance could not be induced in animals devoid of both PP and MLN.
口服抗原后会出现全身低反应性(口服耐受),这涉及肠道相关淋巴组织(GALT)对抗原的摄取和加工,GALT包括派尔集合淋巴结(PP)、固有层淋巴细胞和肠系膜淋巴结(MLN)。肿瘤坏死因子(TNF)家族基因发生靶向突变的动物,其外周淋巴器官(包括PP和MLN)的发育存在不同缺陷,这为研究GALT结构在诱导口服耐受中的作用提供了独特的机会。在既没有PP也没有MLN的TNF/淋巴毒素(LT)α-/-小鼠中无法诱导口服耐受,尽管这些动物可通过腹腔注射抗原实现耐受,这表明诱导口服耐受需要GALT。LTβ-/-小鼠和LTα/LTβ+/-动物没有PP,但通过给予低剂量或高剂量卵清蛋白后检测IFN-γ产生和迟发型超敏反应发现,它们可以实现口服耐受。为了进一步研究对PP的需求,我们检测了经LTβ受体-IgG融合蛋白(LTβRigG)处理的小鼠的后代,这些小鼠不形成PP,但具有完整的免疫系统。尽管这些动物的粪便IgA产生减少,但它们可以实现口服耐受。我们的结果表明,诱导高剂量或低剂量口服耐受并非绝对需要PP,尽管在既没有PP也没有MLN的动物中无法诱导口服耐受。